CSNK2B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL262515	0.67	19/20
SCHEMBL261265	1.00	18/20
SCHEMBL262740	1.00	18/20
SCHEMBL261888	0.74	18/20
SCHEMBL311321	0.67	18/20
SCHEMBL261280	1.00	16/20
SCHEMBL263301	0.73	16/20
SCHEMBL262516	0.69	16/20
SCHEMBL261139	1.00	15/20
SCHEMBL263638	0.74	15/20
SCHEMBL262572	0.71	15/20
SCHEMBL261530	1.00	14/20
SCHEMBL262869	1.00	14/20
SCHEMBL312071	1.00	14/20
SCHEMBL259264	0.48	14/20
SCHEMBL262689	1.00	13/20
SCHEMBL263321	0.80	13/20
SCHEMBL262461	0.70	13/20
SCHEMBL263079	1.00	12/20
SCHEMBL262143	0.76	11/20

Clinical trials — most relevant to CSNK2B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis	PHASE4	COMPLETED
The Efficacy of Computerized Cognitive Remediation Therapy for Chronic Schizophrenia	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19	PHASE2	COMPLETED
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC	PHASE2	COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL	PHASE1/PHASE2	RECRUITING
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
Dose-escalation Study of Oral CX-4945	PHASE1	UNKNOWN
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer	EARLY_PHASE1	COMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
Study of Metabolic Modifications in Children With Noonan Syndrome	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer	nan	UNKNOWN
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation	nan	COMPLETED
Ischemic Preconditioning to Prevent Acute Kidney Injury	nan	COMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults	nan	COMPLETED
New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization	nan	COMPLETED
Longitudinal Study of the Natural History of Duchenne Muscular Dystrophy (DMD)	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
Study of a Candidate Gene Involved in Goldenhar Syndrome.	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CSNK2B binder may also engage these)

Protein	Name	Similarity
P67871	—	1.000	P67871 →
P67869	—	1.000	P67869 →
P67874	—	1.000	P67874 →
P28021	—	1.000	P28021 →
P67873	—	1.000	P67873 →
Q91398	—	1.000	Q91398 →
O76485	—	1.000	O76485 →
P08182	—	1.000	P08182 →
P67872	—	1.000	P67872 →
P67868	—	1.000	P67868 →
Q9NIV2	—	1.000	Q9NIV2 →
Q7KV19	—	0.998	Q7KV19 →
Q24536	—	0.998	Q24536 →
Q7KV12	—	0.996	Q7KV12 →
P40232	—	0.996	P40232 →
O96863	—	0.993	O96863 →
Q7KV15	—	0.992	Q7KV15 →
P28548	—	0.992	P28548 →
Q7KV22	—	0.992	Q7KV22 →
P40228	—	0.992	P40228 →
P40229	—	0.992	P40229 →
Q7KV23	—	0.992	Q7KV23 →
A1ZB91	—	0.991	A1ZB91 →
Q7KV13	—	0.991	Q7KV13 →
Q7KV14	—	0.991	Q7KV14 →
B4GH42	—	0.989	B4GH42 →
O59906	—	0.989	O59906 →
O80507	—	0.989	O80507 →
O94281	—	0.988	O94281 →
Q9TYU5	—	0.988	Q9TYU5 →